Corixa Responds to Court Ruling Regarding BEXXAR Patents.Business Editors/Health/Medical Writers BIOWIRE2K SEATTLE--(BUSINESS WIRE)--Oct. 16, 2003 Corixa (Nasdaq:CRXA) today announced that it expects to appeal, at the earliest opportunity, the recent order of the United States District Court United States District Court In the U.S., any of the 94 trial courts of general jurisdiction in the federal judicial system. Each state, as well as the District of Columbia and the Commonwealth of Puerto Rico, has at least one federal district court. , Southern District of California that BEXXAR patents Nos. 5,595,721, 6,015,542, 6,090,365 and 6,287,537 are invalid based on the finding of inequitable conduct of the inventors. "We are disappointed by the court's opinion, however it should not have any impact on our efforts to successfully commercialize BEXXAR," said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. "We remain committed to enforcing our patent rights on behalf of our shareholders and intend to defend our intellectual property. As a result, we will review the court's order with our legal counsel and commercial partner, GlaxoSmithKline, in the coming days. We currently expect to pursue an appeal with the Federal Circuit to challenge this opinion." About Corixa Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , cancer and infectious diseases by understanding and directing the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . On June 30, 2003, Corixa announced that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved BEXXAR(R) for the treatment of patients with CD20 positive, follicular fol·lic·u·lar adj. 1. Relating to, having, or resembling a follicle or follicles. 2. Affecting or growing out of a follicle or follicles. , NHL NHL Non-Hodgkin's lymphoma, see there , with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. In addition to BEXXAR, Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to and through late stage clinical trials. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, with additional operations in Hamilton, Mont., and South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. . For more information, please visit Corixa's Web site at http://www.corixa.com/. Corixa Forward-Looking Statements This press release contains forward-looking statements, and other statements about our potential appeal of the court order that our BEXXAR patents are invalid and our efforts to commercialize BEXXAR. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that could affect Corixa's actual results include, but are not limited to, our failure to successfully appeal the court's order that BEXXAR patents are invalid, and the "Factors Affecting Our Operating Results, Our Business and Our Stock Price," described in our Quarterly Report on Form 10-Q Form 10-Q See 10-Q. for the quarter ended June 30, 2003, copies of which are available from our investor relations Investor relations The process by which the corporation communicates with its investors. department. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion